Bolt Biotherapeutics
BOLT
71 hedge funds and large institutions have $449M invested in Bolt Biotherapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 11 reducing their positions, and 7 closing their positions.
164% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 11
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
16% more funds holding
Funds holding: 61 → 71 (+10)
0.19% more ownership
Funds ownership: 4.58% → 4.77% (+0.19%)
13% less capital invested
Capital invested by funds: $514M → $449M (-$64.6M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$10.5M |
| 2 |
BlackRock
New York
|
+$7.24M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$5.25M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.89M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$2.32M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$2.19M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.98M |
| 4 |
Morgan Stanley
New York
|
-$1.33M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.14M |
BOLT Hedge Fund Activity: Q3 2021 in Review
71 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q3 2021, worth a combined $449M — down 13% from $514M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BOLT positions and 7 closed out — a net gain of 11 holders — while 29 added to existing stakes and 11 trimmed.
The largest buyer was Samlyn Capital, opening a new position worth an estimated $10.5M. The largest seller was Franklin Resources, exiting entirely with an estimated $2.32M sold.
- 71 institutional investors held Bolt Biotherapeutics (BOLT) as of Q3 2021, up from 61 in Q2 2021.
- Funds reported $449M of Bolt Biotherapeutics stock for Q3 2021, down 13% quarter-over-quarter.
- 18 funds opened new Bolt Biotherapeutics positions in Q3 2021 and 7 closed out, a net change of +11 holders.
- The largest Bolt Biotherapeutics buyer in Q3 2021 was Samlyn Capital, an estimated $10.5M added.
- The largest Bolt Biotherapeutics seller in Q3 2021 was Franklin Resources, an estimated $2.32M sold.
Based on aggregated 13F filings for Q3 2021.